BRISBANE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announces that its President & Chief Executive Officer, Peter Maag, received the 2017 Transplant Innovation Award from TRIO.

TRIO presented its award at their annual meeting in Philadelphia on January 12^th, 2018.

“The award means a lot to our team here at CareDx and to me personally,” said Peter Maag. “Now that AlloSure is available to the kidney transplant community, patient support is critical. In a field that has been waiting for innovative transplant surveillance solutions for years, patients and clinicians finally have a tool to accurately determine allograft health.”

The President of TRIO, Jim Gleason, said, ”We have observed Peter and his team at CareDx for years and their dedication to innovation in the transplant field is noteworthy. The award is well deserved. The current standard of care for allograft surveillance combined with AlloSure shows promise to be an enhanced solution for managing the health of patients and their transplanted organ.”

About TRIO
Transplant Recipients International Organization, Inc. (TRIO) is a non-profit international organization committed to improving the quality of lives touched by the miracle of transplantation through support, advocacy, education, and awareness. Through the TRIO International Office in Virginia, a network of chapters throughout the United States and the world, TRIO provides a range of services to its community, including Awareness, Support, Education, and Advocacy.

Since its incorporation in 1987, TRIO has grown tremendously. A network of chapters with many support groups in varying phases of development provides a peer-counseling support system and facilitates programs to educate the public about the acute need for organ donation.

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap and AlloSure for post-transplant surveillance, and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA typing.

For more information, please visit: www.CareDx.com.

CONTACTS:

TRIO
Jim Gleason
TRIO National president
609-877-4493
gleasonjim@aol.com

CareDx, Inc.
Sasha King
Chief Commercial Officer
415-287-2393
sking@caredx.com

Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com